NeuPath Health (TSXV:NPTH) Mohanram G-Score: 5 (As of Jun. 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:NPTH NeuPath Health Inc TSXV:NPTH
39 GF Score
Price C$0.55
GF Value C$0.25
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is NeuPath Health Mohanram G-Score?

NeuPath Health TSXV:NPTH 39 Mohanram G-Score is 5 as of Jun. 2026, which is at its 10-year median of 5.00. GuruFocus rates TSXV:NPTH with a GF Score™ of 39/100 and a GF Value™ of C$0.25 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Mohanram G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. Companies have higher G-score tends to generate higher return. According to his study, the best growth stocks that have a G-Score greater than 6 tend to beat the market, while those with a G-Score lower than 1 tend to have negative absolute returns.

Thus, the zones of discrimination were as such:

Good or high score = 6, 7, 8
Bad or low score = 0, 1

NeuPath Health has an G-score of 5.

The historical rank and industry rank for NeuPath Health's Mohanram G-Score or its related term are showing as below:

TSXV:NPTH' s Mohanram G-Score Range Over the Past 10 Years
Min: 5   Med: 5   Max: 5
Current: 5

During the past 7 years, the highest Piotroski G-score of NeuPath Health was 5. The lowest was 5. And the median was 5.

NeuPath Health  (TSXV:NPTH) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


NeuPath Health Mohanram G-Score Related Terms


NeuPath Health Mohanram G-Score Historical Data

* Premium members only.

The historical data trend for NeuPath Health's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuPath Health Mohanram G-Score Chart

NeuPath Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Mohanram G-Score
Get a 7-Day Free Trial N/A N/A N/A N/A 5.00

NeuPath Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 5.00 5.00 5.00 5.00

TSXV:NPTH vs HCA, THC, DVA: Mohanram G-Score Comparison

For the Medical Care Facilities subindustry, NeuPath Health's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuPath Health Mohanram G-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NeuPath Health's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where NeuPath Health's Mohanram G-Score falls into.


TSXV:NPTH
39GF Score
NeuPath Health Inc TSXV:NPTH
Mohanram G-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuPath Health Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

NeuPath Health has an G-score of 5.

Frequently Asked Questions Learn more about Mohanram G-Score →
What does a Mohanram G-Score of 5 mean?
NeuPath Health (TSXV:NPTH) has a Mohanram G-Score of 5 as of Jun. 2026. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on NeuPath Health and its competitors. This is near median its historical median of 5.00. Over the past decade, NeuPath Health's Mohanram G-Score has ranged from 5.00 to 5.00.
Is NeuPath Health's Mohanram G-Score too high?
NeuPath Health's current Mohanram G-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 5.00. Overall, NeuPath Health has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuPath Health's Mohanram G-Score compare to HCA and THC?
NeuPath Health's Mohanram G-Score of 5 can be compared against companies in the Healthcare Providers & Services industry. Historically, NeuPath Health's own Mohanram G-Score has ranged from 5.00 to 5.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Mohanram G-Score for a Healthcare Providers & Services company?
A good Mohanram G-Score depends on the Healthcare Providers & Services industry context. However, Mohanram G-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Mohanram G-Score mean?
A high Mohanram G-Score can signal that a stock is expensive relative to its fundamentals. G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. View historical data on NeuPath Health and its competitors. NeuPath Health's current Mohanram G-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuPath Health stock overvalued right now?
Based on GuruFocus' analysis, NeuPath Health (TSXV:NPTH) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.25, compared to a current price of C$0.55 — trading 120% above its estimated fair value. The current Mohanram G-Score is 5, which is near median its 10-year median of 5.00. NeuPath Health's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Mohanram G-Score calculated?
Mohanram G-Score is calculated from a company's financial statements. For NeuPath Health (TSXV:NPTH), the current Mohanram G-Score is 5 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeuPath Health (TSXV:NPTH) Overvalued in 2026?

Based on GuruFocus' analysis, NeuPath Health stock appears to be overvalued. The current stock price of C$0.55 is trading 120% above its estimated GF Value™ of C$0.25. GuruFocus considers NeuPath Health to be Significantly Overvalued.

Key valuation signals for TSXV:NPTH:

  • Mohanram G-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: C$0.25 vs. price of C$0.55 (120% above fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the TSXV:NPTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NeuPath Health Business Description

Address 181 Bay Street, Suite 2100, Toronto, ON, CAN, M5J 2T3
NeuPath Health Inc operates an end-to-end, integrated network of healthcare businesses. It utilizes research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by acute and chronic musculoskeletal conditions, including chronic pain, spinal injuries, sports-related injuries, and concussions. It operates an interdisciplinary network of medical clinics in Ontario and Alberta, in addition to an independent medical assessment business with a national network of healthcare providers. Its medical clinics provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal or back injuries, sports-related injuries, and concussions. The company operates in one industry segment: medical services.
39GF Score

Get the complete analysis for TSXV:NPTH

Mohanram G-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.55
Price
C$0.25
GF Value